ECCO 2022

Microbiota manipulation: Still a lot to learn

The potential of histology in Crohn´s disease and how AI will contribute

Combination trials open a new door in IBD treatment

Combined endpoints as new therapy goals

Light at the end of the Pouchitis track

Is the continuation of combination therapy the key to success in CD?

Is stopping of therapy an option in CD?

SPARE study in ECCO 2022

Will we improve the management of IBD by combining biologics?

FMT is not a promising option for UC patients

A negative control trial for FMT in UC

A new opportunity for proactive TDM disease control

Withdrawal of infliximab or anti-metabolite therapy in CD in sustained remission

Combination of biologics

Combination with different classes of drugs in moderate to severe UC

The first combination therapy trial

Proactive TDM or SOC for monitoring infliximab treatment in immun-mediated patients?

The interleukin-17 conundrum

FMT in UC - still far away from the success story

How to deescalate treatment in CD?

Proactive TDM

Combination of biologics - finally arrived in IBD!?

Infliximab withdrawl leeds to a higher risk of (reversible) relapse in Crohn's disease

When to withdraw therapy in crohn's disease?

Ustekinumab for fistulizing disease

Is the speedity of the steroid tapering important during initiation of infliximab?

Filgotinib for fistulizing disease

FMT ist kein vielversprechender Ansatz für UC-Patienten

Una nuova opportunità per i TDM nel controllo proattivo di malattia

Combinazione di biologici

Επηρεάζει η ταχύτητα διακοπής των κορτικοστεροειδών την αποτελεσματικότητα της θεραπείας με infliximab

Allons nous améliorer la prise en charge des MICI en combinant les traitements biologiques?

FMT w colitis ulcerosa - wciąż daleko od sukcesu

מחקר SPARE ב ECCO 2022

Ist der Therapiestopp eine Option in CD?

Προληπτική μέτρηση των θεραπευτικών επιπέδων του φαρμάκου (TDM) ή κλασική παρακολούθηση της θεραπείας με infliximab σε ασθενείς με ανοσιακά νοσήματα

Wann Beendigung von Infliximab oder Immunmodulatoren bei M. Crohn?

Kombination von Biologika - endlich bei IBD angekommen!?

Il primo trial di terapia biologica di combinazione

Du nouveau sur l’allégement thérapeutique au cours de la maladie de Crohn

Das Interleukin-17 Rätsel

Un essai négatif sur la transplantation de microbiote dans la RCH

Can we translate rheumatoid arthritis to ulcerative colitis?

Is combination therapy safe?

COVID-19: still a moving target!

Which IBD patients have a higher risk of safety concerns?

Inflammatory bowel disease and cancer risk

A touch of the near future in IBD treatment

Breastmilk is tuning IBD risk

The heart is apparently safe with continuous Ozanimod treatment

Muttermilch beeinflusst das IBD-Risiko

Uno sguardo al prossimo futuro nel trattamento delle IBD

Il cuore sembra essere apparentemente al sicuro durante il trattamento continuativo con ozanimod

Vedolizumab: promising data for pouchitis and IBD in children

Mucosal healing: Will efficacy data translate into real world?

Efficacy update on JAKis

Fistulizing Crohn‘s disease - new treatment options with JAKis and IL-12/IL-23 inhibition

The race is on IL-23 – exciting data for CD and UC

Selective IL-23 blockade

Anti-IL-23 - a turning point?

Great news on pouchitis treatment - vedolizumab effective

Guselkumab as maintenace treatment in Crohn's Disease

Vedolizumab in chronic pouchitis - a new chapter in therapeutic algorithms?

New ways of treatment

JAK inhibition

New opportunity in pouchitis treatment

Upadacitinib - will it be the game changer in UC?

Vedolizumab is effective in chronic pouchitis after IPAA for UC

Selektive IL-23 Blockade

JAK-Inhibition

Guselkumab come terapia di mantenimento

Anti-IL-23 - eine Zeitenwende?

Upadacitinib - nowy lek, duże nadzieje

Nuevos caminos en el tratamiento

Wedolizumab w pouchitis - początek nowego rozdziału w terapii?

Una nuova opportunità nel trattamemto della pouchite

New goals for IBD

New therapeutic goals in UC

Disease control is possible!

Natural history of anal ulcerations in pediatric-onset CD

New therapy goals: urgency and disease clearance

Patient relevant outcomes also show efficacy of upadacitinib in UC

Histological findings in mirikizumab treatment

Histoire naturelle de la maladie de Crohn ano-périnéale pédiatrique

Urgency und Disease Clearance

Nuevas objetivos en las EII

Disease Control ist möglich!

COVID-19 in patients with IBD stratified acc. to therapy

The efficacy of COVID-19 vaccines in IBD - what's new?

תגובה חיסונית לחיסונים כנגד קורונה בחולים עם מחלות מעי דלקתיות מרובדים לפי טיפול

Skuteczność szczepień przeciw COVID-19 w IBD - nowe dane

Point of Care Testing / AI / Telemedicine

Ultrasound as a predictor of treatment response

Digitale Tools, KI und Telemedizin

Ultraschall als Prädiktor des Therapieansprechens

ECCO guidelines on pregnancy

Spanish women leading contribution to ECCO 2022

Las mujeres lideran la contribución española a la ECCO 2022

ECCO Richtlijnen zwangerschap